Wall Street analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report sales of $10.20 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $9.58 million and the highest is $10.82 million. BioCryst Pharmaceuticals posted sales of $9.44 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.1%. The firm is expected to report its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $10.20 million for the current year, with estimates ranging from $16.75 million to $28.61 million. For the next fiscal year, analysts forecast that the business will post sales of $24.60 million per share, with estimates ranging from $23.02 million to $26.18 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. The firm had revenue of $3.89 million for the quarter, compared to analyst estimates of $6.07 million. During the same period in the prior year, the company posted ($0.06) EPS. The firm’s quarterly revenue was down 56.7% compared to the same quarter last year.
Several institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in shares of BioCryst Pharmaceuticals by 6.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,116 shares of the biotechnology company’s stock valued at $351,000 after acquiring an additional 3,774 shares during the last quarter. Voya Investment Management LLC increased its position in shares of BioCryst Pharmaceuticals by 12.1% in the 2nd quarter. Voya Investment Management LLC now owns 38,275 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 4,127 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock valued at $1,678,000 after buying an additional 12,267 shares in the last quarter. American International Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 22.9% in the 4th quarter. American International Group Inc. now owns 66,002 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 12,317 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 183,643 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 13,306 shares in the last quarter. Institutional investors own 91.54% of the company’s stock.
BCRX stock remained flat at $$5.21 during trading hours on Friday. The company’s stock had a trading volume of 841,344 shares, compared to its average volume of 1,252,155. BioCryst Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $8.99. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.23. The stock has a market cap of $519.65, a price-to-earnings ratio of -6.74 and a beta of 2.63.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.